Skip to main content

Rosetta Genomics, US Genomics to Develop miRNA-Based Test for Lung Cancer

NEW YORK, May 24 (GenomeWeb News) - Rosetta Genomics and US Genomics today said that they will co-develop an microRNA-based, non-invasive early-detection test for lung cancer.

 

The collaboration will pair US Genomics' Trilogy 2020 platform and Direct miRNA assay with Rosetta Genomics' microRNAs to create a molecular diagnostic that uses a blood sample to identify lung cancer, according to the firms.

Financial details were not discussed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.